Carcinoma of the Cervix
Histopathology Reporting Guide

PRIOR TREATMENT (Note 1)

Previous procedure performed
- Loop
- Cone
- Trachelectomy (simple or radical)
- Other, specify

Previous therapy
- Chemotherapy
- Radiation
- Chemoradiation
- Other, specify

SPECIMENS SUBMITTED (select all that apply) (Note 2)
- Loop excision*
- Cone biopsy
- Trachelectomy
  - Simple
  - Type not specified
- Hysterectomy
  - Simple
  - Part of exenteration
- Left tube
- Left ovary
- Left parametrium
- Vaginal cuff
- Pelvic exenteration
  - Urinary bladder
  - Vagina
  - Other, specify
- Lymphadenectomy specimen(s)
  - Sentinel node(s)
  - Regional nodes: pelvic
  - Regional nodes: para-aortic
  - Non-regional nodes: inguinal
  - Other node group

SPECIMEN DIMENSIONS (Note 3)

Number of tissue pieces**

Tissue piece dimensions** (Note: Record for each piece)

Cervix***

DIAMETER OF ECTOCERVIX

DEPTH OF SPECIMEN

Vaginal cuff****

MINIMUM LENGTH

MAXIMUM LENGTH

Left parametrium

Left lateral extent

Right parametrium

Right lateral extent

MACROSCOPIC APPEARANCE OF TUMOUR(S) (Note 4)
- No macroscopically visible tumour
- Exophytic/polypoid
- Flat
- Ulcerated
- Circumferential/barrel shaped cervix

* Loop excision includes – loop electrosurgical excision procedure (LEEP) and large loop excision of the transformation zone (LLETZ).
<table>
<thead>
<tr>
<th>MACROSCOPIC TUMOUR SITE(S) (select all that apply) (Note 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ No macroscopically visible tumour</td>
</tr>
<tr>
<td>☐ Indeterminate</td>
</tr>
<tr>
<td>▼ Ectocervix</td>
</tr>
<tr>
<td>☐ Anterior</td>
</tr>
<tr>
<td>☐ Posterior</td>
</tr>
<tr>
<td>☐ Left lateral</td>
</tr>
<tr>
<td>☐ Right lateral</td>
</tr>
<tr>
<td>☐ Circumference of cervix</td>
</tr>
<tr>
<td>▼ Endocervix</td>
</tr>
<tr>
<td>☐ Anterior</td>
</tr>
<tr>
<td>☐ Posterior</td>
</tr>
<tr>
<td>☐ Left lateral</td>
</tr>
<tr>
<td>☐ Right lateral</td>
</tr>
<tr>
<td>☐ Circumference of cervix</td>
</tr>
<tr>
<td>☐ Vagina</td>
</tr>
<tr>
<td>☐ Uterus</td>
</tr>
<tr>
<td>▼ Lower uterine segment</td>
</tr>
<tr>
<td>☐ Corpus</td>
</tr>
<tr>
<td>▼ Parametrium</td>
</tr>
<tr>
<td>☐ Left</td>
</tr>
<tr>
<td>☐ Right</td>
</tr>
<tr>
<td>▼ Other organs or tissues, specify</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BLOCK IDENTIFICATION KEY (Note 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(List overleaf or separately with an indication of the nature and origin of all tissue blocks)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TUMOUR DIMENSIONS (Note 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(If separate tumours specify the dimensions for each tumour)</td>
</tr>
<tr>
<td>☐ Tumour dimensions cannot be determined</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Horizontal extent</th>
<th>mm x mm At least*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depth of invasion</td>
<td>mm At least*</td>
</tr>
<tr>
<td>OR ☐ Not assessable</td>
<td></td>
</tr>
<tr>
<td>If not assessable record:</td>
<td></td>
</tr>
<tr>
<td>Thickness</td>
<td>mm</td>
</tr>
</tbody>
</table>

* It is advisable to include "at least" for the tumour measurements in loop or cone excisions when tumour is present at a resection margin/s. If not applicable, delete "at least".

<table>
<thead>
<tr>
<th>HISTOLOGICAL TUMOUR TYPE (Note 8)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>HISTOLOGICAL TUMOUR GRADE (Note 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not graded/applicable</td>
</tr>
<tr>
<td>☐ G1: Well differentiated</td>
</tr>
<tr>
<td>☐ G2: Moderately differentiated</td>
</tr>
<tr>
<td>☐ G3: Poorly differentiated</td>
</tr>
<tr>
<td>☐ GX: Cannot be graded</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LYMPHOVASCULAR INVASION (Note 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not identified</td>
</tr>
<tr>
<td>☐ Indeterminate</td>
</tr>
<tr>
<td>☐ Present</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COEXISTENT PATHOLOGY (Note 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Required for loop/cone excisions/trachelectomies only and recommended for other specimens)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Squamous intraepithelial lesion (SIL) (CIN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not identified</td>
</tr>
<tr>
<td>☐ Present</td>
</tr>
<tr>
<td>GRADE</td>
</tr>
<tr>
<td>☐ Low-grade SIL (LSIL) (CIN 1)</td>
</tr>
<tr>
<td>☐ High-grade SIL (HSIL) (CIN 2/3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adenocarcinoma in-situ (AIS)/High-grade cervical glandular intraepithelial neoplasia (HG CGIN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not identified</td>
</tr>
<tr>
<td>☐ Present</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stratified mucin-producing intraepithelial lesion (SMILE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not identified</td>
</tr>
<tr>
<td>☐ Present</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other possible precursor lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not identified</td>
</tr>
<tr>
<td>☐ Present</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXTENT OF INVASION (Note 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not applicable</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vagina</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
<tr>
<td>▼ Upper two thirds</td>
</tr>
<tr>
<td>▼ Lower third</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lower uterine segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endometrium</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Myometrium</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parametrium</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
<tr>
<td>▼ Left</td>
</tr>
<tr>
<td>▼ Right</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fallopian tube</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Not involved</td>
</tr>
<tr>
<td>☐ Involved</td>
</tr>
<tr>
<td>▼ Left</td>
</tr>
<tr>
<td>▼ Right</td>
</tr>
</tbody>
</table>
### Ovary
- Not involved
- Involved
  - Left
  - Right
- Not applicable

### Bladder
- Not involved
- Involved, specify compartment
- Not applicable

### Rectum
- Not involved
- Involved, specify compartment
- Not applicable

### Other organs or tissues
- Not involved
- Involved, specify
- Not applicable

## Margin Status (Note 13)

### For carcinoma

**HYSTERECTOMY/TRACHELECTOMY SPECIMEN**

<table>
<thead>
<tr>
<th>Margin</th>
<th>Involved</th>
<th>Not involved</th>
<th>Distance from tumour (mm)</th>
<th>Cannot be assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ectocervical/vaginal cuff</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocervical <strong>^</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radial/deep stromal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Closest lateral</td>
<td>Left</td>
<td>Right</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**LOOP/CONE**

<table>
<thead>
<tr>
<th>Margin</th>
<th>Involved</th>
<th>Not involved</th>
<th>Distance from tumour (mm)</th>
<th>Cannot be assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ectocervical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocervical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radial/deep stromal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unspecified <strong>^^</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### For preinvasive disease

<table>
<thead>
<tr>
<th>Margin</th>
<th>HSIL Involved</th>
<th>HSIL Not involved</th>
<th>AIS Involved</th>
<th>AIS Not involved</th>
<th>SMILE Involved</th>
<th>SMILE Not involved</th>
<th>SMILE Cannot be assessed</th>
<th>Margin not applicable to specimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ectocervical/vaginal cuff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocervical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radial/deep stromal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unspecified <strong>^^</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**^** This is required only for trachelectomy specimens.

**^^** Use for loop/cone biopsies where it is not possible to say whether the margin is ectocervical or endocervical.

## Pathologically Confirmed Distant Metastases (Note 14)

- Not identified
- Present, specify site(s)

## Ancillary Studies (Note 15)

**Performed**

- HPV testing, specify details

**Not performed**

- Immunohistochemistry, specify details

- Other, specify details
### LYMPH NODE STATUS (Note 16)

- Not submitted

*** If the actual number of lymph nodes examined or the number of positive nodes cannot be determined due, for example, to fragmentation, then this should be indicated in the response.

### PROVISIONAL PATHOLOGICAL STAGING PRE-MDTM (Note 17)

**FIGO (2018 edition)** (Reproduced with permission)

#### Stage I:
The carcinoma is strictly confined to the cervix uteri (extension to the corpus should be disregarded)

- **IA** Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion <5 mm
  - IA1 Measured stromal invasion <3 mm in depth
  - IA2 Measured stromal invasion ≥3 mm and <5 mm in depth
- **IB** Invasive carcinoma with measured deepest invasion ≥5 mm (greater than stage IA), lesion limited to the cervix uteri
  - IB1 Invasive carcinoma ≥5 mm depth of stromal invasion and <2 cm in greatest dimension
  - IB2 Invasive carcinoma ≥2 cm and <4 cm in greatest dimension
  - IB3 Invasive carcinoma ≥4 cm in greatest dimension

#### Stage II:
The carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall

- **IIA** Involvement limited to the upper two-thirds of the vagina without parametrical involvement
  - IIA1 Invasive carcinoma <4 cm in greatest dimension
  - IIA2 Invasive carcinoma ≥4 cm in greatest dimension
- **IIB** With parametrical involvement but not up to the pelvic wall

#### Stage III:
The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or paraaortic lymph nodes

- **IIIA** Carcinoma involves the lower third of the vagina, with no extension to the pelvic wall
- **IIIB** Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to another cause)
- **IIIC** Involvement of pelvic and/or paraaortic lymph nodes, irrespective of tumor size and extent (with r and p notations)
  - IIIC1 Pelvic lymph node metastasis only
  - IIIC2 Paraaortic lymph node metastasis

#### Stage IV:
The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bulous edema, as such, does not permit a case to be allotted to stage IV

- **IVA** Spread to the growth to adjacent organs
- **IVB** Spread to distant organs

---

### TNM STAGING (UICC TNM 8th edition 2016)**

#### TNM Descriptors

- m - multiple primary tumors
- r - recurrent
- y - post-therapy

#### Primary tumour (pT)

- **T0** No evidence of primary tumour
- **Tis** Carcinoma in situ (preinvasive carcinoma)
- **T1** Tumour confined to the cervix
  - T1a Carcinoma diagnosed only by microscopy; stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less
  - T1a1 Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread
  - T1b Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2
  - T1b1 Clinically visible lesion 4.0 cm or less in greatest dimension
  - T1b2 Clinically visible lesion more than 4.0 cm in greatest dimension
- **T2** Tumour invades beyond uterus but not to pelvic wall or to lower third of vagina
  - T2a Tumour without parametrical invasion
  - T2a1 Clinically visible lesion 4.0 cm or less in greatest dimension
  - T2a2 Clinically visible lesion more than 4.0 cm in greatest dimension
- **T3** Tumour extends to pelvic wall, involves lower third of vagina, causes hydronephrosis or nonfunctional kidney
  - T3a Tumour involves lower third of vagina
  - T3b Tumour extends to pelvic wall, causes hydronephrosis or nonfunctional kidney
  - T4 Tumour invades mucosa of bladder or rectum or extends beyond true pelvis

---

### Regional lymph nodes (pN)

- **NX** Regional lymph nodes cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Regional lymph node metastasis

---

**Note 16**

- The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.
- Imaging and pathology can be used, when available, to supplement clinical findings with respect to tumor size and extent, in all stages.

---

**Note 17**

- Extension to the corpus uteri should be disregarded.
- The depth of invasion should be taken from the base of the epithelium, either surface or glandular, from which it originates.
- The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction of the adjacent most superficial papillae to the deepest point of invasion.
- All macroscopically visible lesions even with superficial invasion are T1b/IB.
- Vascular space involvement, venous or lymphatic, does not affect classification. A bulous edema is not sufficient to classify a tumour as T4.
Definitions

CORE elements

CORE elements are those which are essential for the clinical management, staging or prognosis of the cancer. These elements will either have evidentiary support at Level III-2 or above (based on prognostic factors in the NHMRC levels of evidence). In rare circumstances, where level III-2 evidence is not available an element may be made a CORE element where there is unanimous agreement in the expert committee. An appropriate staging system e.g. Pathological TNM staging would normally be included as a CORE element.

The summation of all CORE elements is considered to be the minimum reporting standard for a specific cancer.

NON-CORE elements

NON-CORE elements are those which are unanimously agreed should be included in the dataset but are not supported by level III-2 evidence. These elements may be clinically important and recommended as good practice but are not yet validated or regularly used in patient management.

Key information other than that which is essential for clinical management, staging or prognosis of the cancer such as macroscopic observations and interpretation, which are fundamental to the histological diagnosis and conclusion e.g. macroscopic tumour details, may be included as either CORE or NON-CORE elements by consensus of the Dataset Authoring Committee.

Scope

This dataset has been developed for the pathology reporting of primary cervical carcinomas. Specimens include loop/cone excisions, trachelectomies, simple and radical hysterectomies and exenterations. The dataset applies to epithelial neoplasms only and does not apply to small biopsy specimens.

The second edition of this dataset includes changes to align the dataset with the 2018 revised International Federation of Gynecology and Obstetrics (FIGO) staging for carcinoma of the cervix uteri.

Note 1 - Prior treatment (Non-core)

Prior chemotherapy, chemoradiation and radiation therapy may significantly alter the original tumour size. Patients with FIGO 2018 clinical stage IB3 and greater cervical cancer (with the exception of IIA1) usually receive chemotherapy, radiation or chemoradiation and this is followed by hysterectomy in some institutions. Studies have shown that the cervical tumour totally disappears in the majority of the cases with only a third of hysterectomy specimens containing residual tumour after neoadjuvant chemoradiation. Chemotherapy, chemoradiation or radiation may also introduce histological changes that were not present in the untreated tumour, such as multinucleate tumour giant cells and degenerate nuclei. Metastatic carcinomas may mimic primary cervical malignancies and knowledge of the patient’s cancer history is important for the diagnostic workup (immunohistochemistry or molecular studies) of a newly discovered cervical malignancy. Finally, histological findings (tumour size, histological type and grade and sometimes other parameters) in a prior cervical loop or cone excision may be important for the ultimate tumour staging and grading in a hysterectomy specimen. In patients with a prior loop excision, the size of the tumour in the
original loop has to be taken into consideration in determining the overall tumour size (see NOTE 7 - TUMOUR DIMENSIONS).2,7

Note 2 – Specimen(s) submitted (Core)

The type of operative procedure undertaken, such as a simple or radical hysterectomy, is defined by the surgeon. A radical trachelectomy or hysterectomy includes parametrectomy with resection of the parametrical node-bearing tissue. While the nature of the specimen(s) submitted for pathological assessment can usually be deduced from the procedure, in some cases the tissue submitted may be incomplete or include more components than expected and therefore specifying the anatomical structures included in the specimen(s) provides complementary information and confirmation that entire organ(s) have been resected and submitted.

Gynaecological oncologists typically divide lymph nodes into anatomical sub-groups and this should be documented in the report.

Note 3 - Specimen dimensions (Core and Non-core)

Cervical specimens include loop/cone excisions, simple and radical hysterectomies, simple and radical trachelectomies, and pelvic exenterations. The cervix is a cylindrical structure and taking into account the various surgical procedures that are carried out to remove it, this means that a conventional approach to measuring the size of the cervix in 3 dimensions is difficult to apply. Measurement is further complicated by differences between laboratories in how they fix and grossly examine the specimens. In loop/cone excisions and trachelectomies, the diameter of the ectocervix (two dimensions) and the depth (thickness) of the specimen should be recorded in millimetres (mm). The metric should be accurate and reproducible since it may be important for documentation, diagnostic and prognostic purposes and therapeutic decision-making.

The minimum and maximum cranio-caudal lengths of the vaginal cuff, when present, should be measured in mm. If a parametrectomy has been performed, a measurement from the side of the uterus to the lateral edge of each unstretched parametrium (lateral extent) should be recorded in mm. Surgically dissected parametrium (formal parametrectomy) is not part of a simple hysterectomy specimen. Fragments of paracervical/parametrial soft tissue may be included in the sections of cervix from a simple hysterectomy. Some pathologists may submit this tissue as a paracervical/parametrial shave. Although paracervical/parametrial tissue is present, this does not represent a formal parametrectomy.

Note 4 - Macroscopic appearance of tumour(s) (Non-core)

Documentation of the macroscopic appearance of cervical tumours allows correlation with the clinical and radiological assessment of the tumour. According to FIGO 2018, clinically visible cervical cancers are, by definition, FIGO stage IB1 at least.8 However, on histological examination, sometimes the stage is lower than clinically expected, for example if there is an associated lesion such as an erosion, and if the lesion has the dimensions of a IA neoplasm, it is recommended that it should be categorised as such. This should also be discussed at the gynaecological oncology tumour board/ multidisciplinary team meeting (MDTM).
Exophytic/polypoid carcinomas may have a growth pattern that results in very little or even no invasion of the underlying stroma and ulcerated tumours may entirely or predominantly supplant the surface epithelium. In both these circumstances, it may be necessary to measure tumour “Thickness” rather than “Depth of Invasion” and it is helpful to document the macroscopic appearance to provide context and explanation for the use of the alternative measurements. In large circumferential tumours, there is a risk of overestimating the maximum horizontal extent of the tumour (see NOTE 7 - TUMOUR DIMENSIONS). Bulky (> 4 cm) barrel-shaped cervical tumours had a significantly worse overall and disease-free survival in one study, but bulky exophytic cervical tumours had the same surgical morbidity, overall and disease-free survival as non-bulky cervical tumours.9

The macroscopic appearance of the tumour influences tumour sampling. For cases where there is no macroscopically visible tumour either because there has been a prior surgical procedure or prior therapy the entire cervix should be blocked. For cases with a large visible tumour, it is not necessary to block the whole tumour, but instead careful block selection ensuring representative sampling of the tumour, accurate assessment of margins and tumour extent is required. The blocks should be taken to include the nearest margin(s) and show the maximum depth of stromal invasion. In departments where the facility for processing oversize blocks is available, a good overview of the tumour and resection margins can be obtained. In departments where this facility is not available, large blocks may need to be subdivided; in such cases, the relationship of the blocks to one another should be clearly documented.

Note 5 – Macroscopic tumour site (Core)

The gross location of cervical tumours in all resection specimens, including hysterectomy specimens and tracheectomies, must be documented. In addition to providing the tumour dimensions (see NOTE 7 - TUMOUR DIMENSIONS) and the proximity of the tumour to surgical resection margins, the relationship to local anatomical structures such as the vaginal cuff, the resected parametrial tissue (if present) as well as involvement of the lower uterine segment and uterine corpus should be documented. Because there may be an increased risk of para-aortic lymph node spread10 and a higher rate of ovarian metastases11 in cases with invasion of the uterine corpus, the presence of macroscopic involvement of the uterine corpus should be recorded.

The exact anatomical location of the cervical tumour should be stated (e.g. anterior or posterior cervical lip, right or left lateral, ectocervix or endocervix) and it may be helpful to provide a precise location according to the position on a clock face for localised tumours, or to specify circumferential cervical involvement when appropriate. Specifying the exact site of the tumour allows detailed comparison with radiological findings and also facilitates careful block selection and embedding of tissue slices with respect to the resection margins. Sometimes in cases where a previous loop excision has been undertaken or prior chemotherapy, chemoradiation or radiation therapy has been administered, no grossly visible tumour is identified in the hysterectomy or tracheectomy specimen. In the event that sub-categorisation of the tumour site with respect to laterality or anterior/ posterior location is not possible (for example, in an unorientated tracheectomy specimen), then only the main/primary site, (ectocervix, endocervix etc) should be recorded.

Note 6 - Block identification key (Non-core)

The origin/designation of all tissue blocks should be recorded. This information should ideally be documented in the final pathology report and is particularly important should the need for internal or external review arise. The reviewer needs to be clear about the origin of each block in order to provide an
informed specialist opinion. If this information is not included in the final pathology report, it should be available on the laboratory computer system and relayed to the reviewing pathologist. It may be useful to have a digital image of the specimen and record of the origin of the tumour blocks in some cases.

Recording the origin/designation of tissue blocks also facilitates retrieval of blocks for further immunohistochemical or molecular analysis, research studies or clinical trials.

Note 7 – Tumour dimensions (Core)

Reasons for accurate tumour measurement

Measurement of tumour dimensions in cervical carcinomas is important for accurate FIGO staging of early cervical cancers, patient management and patient prognostication. Tumours should be measured in mm in three dimensions, namely two measurements of horizontal extent and the depth of invasion (Figure 1). There are multiple problems with regard to measuring cervical tumours and these are discussed in detail in this section. In addition, it may not be possible to provide accurate tumour dimensions in fragmented or thermally damaged specimens. In situations where the tumour extends to resection margins, the tumour dimensions should be qualified by use of the term ‘at least’ to indicate that the measurements may not indicate the true/final tumour size.

In most datasets, separate gross and microscopic measurements are mandated but this may result in confusion if different measurements are given. Some tumours (especially larger ones) are more accurately measured grossly while others (especially smaller tumours and some larger tumours with a diffusely infiltrative pattern or with marked tumour associated fibrosis) are best measured (or can only be measured) microscopically. In this dataset, separate gross and microscopic measurements are not included but rather one set of measurements is required which is based on a correlation of the gross and microscopic features with gross examination being more important in some cases and microscopic examination in others. A few other points are emphasised:-

1. In providing the final tumour dimensions, the measurements in any prior specimens, for example loop/cone excisions, will need to be taken into account. Although it may overestimate the maximum horizontal extent, it is recommended to add together the maximum horizontal measurement in different specimens when calculating the final horizontal extent. The depth of invasion can be taken as the maximum depth of invasion in the two different specimens. Similar comments pertain if loop/cone excisions are received in more than one piece and where multifocal tumour can be excluded.

2. Many cervical carcinomas of large size or advanced stage are treated by chemoradiation, without surgical resection, once the diagnosis has been confirmed on a small biopsy specimen. In such cases, the tumour dimensions will be derived from clinical examination and the radiological appearances. As indicated previously, this dataset applies only to excision/resection specimens and not to small biopsy specimens.

3. Occasionally resections are undertaken following chemoradiation for cervical carcinoma. In such cases, there may be no residual tumour or only small microscopic foci making it impossible to assess the tumour dimensions. In such cases, the pre-treatment clinical or radiological tumour dimensions should be used for staging and the dimensions of the tumour in the resection should not be used for staging purposes.

Specific situations where tumour measurements are important

These include:-
1. Small carcinomas where accurate measurement is paramount in distinguishing between FIGO stage IA1, IA2 and small IB1 neoplasms. As well as providing an accurate stage, this may also be critical in dictating patient management. For example, FIGO IA1 neoplasms are often treated by local excision ensuring that the margins are clear of pre-invasive and invasive disease while IA2 and IB1 neoplasms are usually treated by radical surgery (radical hysterectomy or trachelectomy).

2. In patients with FIGO stage IB tumours treated by radical hysterectomy, the tumour size is often one of the parameters used (in conjunction with tumour differentiation, presence or absence of lymphovascular invasion (LVI) and distance to margins) in assessing the need for adjuvant therapy.

3. The tumour measurements may be important in helping to determine whether radical hysterectomy or trachelectomy is performed; sometimes a cut-off size of 2 cm is used for performing a radical trachelectomy, although some surgeons would still perform this procedure for larger size lesions. Following radical trachelectomy, the recurrence rate is statistically higher with tumour size greater than 2 cm and rates of adjuvant treatment are higher. There is also a trend towards more conservative surgery (simple as opposed to radical hysterectomy) in patients with tumours less than 2 cm as the probability of parametrial infiltration is very low.

4. Several studies have shown that in FIGO stage IB1 cervical carcinomas, a cut-off size of 2 cm may be of prognostic value. In the 2018 FIGO staging system, a cut-off of 2 cm distinguishes between IB1 and IB2 carcinomas. A cut-off of 4 cm is also of prognostic significance and in FIGO 2018 distinguishes between FIGO IB2 and IB3neoplasms and between IIA1 and IIA2 neoplasms.

Measurement of horizontal extent of tumour (Figures 1 and 2)

The horizontal extent (two dimensions, i.e. both tumour length and width, measurements ‘b’ and ‘c’ in Figure 1) must be measured in all cases. As discussed earlier, in large tumours, this may best be done grossly if large block processing is not available, because in many cases these neoplasms will need to be submitted in multiple cassettes and the maximum tumour dimension may not be represented on a single slide. If a gross measurement is not performed in large circumferential tumours, there is a risk of overestimating the maximum horizontal extent of the tumour. This can occur when a circumferential tumour is “opened-up” and submitted in several sequential cassettes. When the other horizontal dimension (the third dimension) is calculated by adding up sequential slices in this situation (see below), this may result in an artificially greater measurement than is accurate.

In smaller neoplasms, the horizontal extent is best determined histologically (Figure 2). One dimension is the measurement in a single slide in which the extent of invasion is the greatest (measurement ‘e’, Figure 2). If the invasive focus is only represented in 1 block, then the other horizontal dimension is taken to be the thickness of the block (usually 2.5-3 mm, or estimated as indicated below). In some cases, the maximum horizontal extent may need to be calculated in the manner below if this is not represented in one section but is spread over several adjacent sections (measurement ‘c’, Figure 1). If invasive carcinoma is present in several adjacent sections of tissue and the invasive foci co-localise in the sections, the horizontal extent of the carcinoma should be calculated by an estimate of the thickness of the blocks, which is determined from the macroscopic dimensions of the specimen and the number of blocks taken. However, pathologists should be mindful that thickness of large or outsize blocks can vary from block to block, as compared with standard-sized blocks. Whilst it is acknowledged that measurements from calculating block thickness may be somewhat inaccurate, it will in some cases be the only way to determine the maximum horizontal extent and this may affect staging, especially in small tumours. A few points regarding measurement of the horizontal extent of tumours are listed below:-

1. in a case where a single tongue of stromal invasion is seen in continuity with the epithelium of origin (surface or glandular), the width of the single focus of invasion is measured across the invasive tongue.

2. where clustered foci of stromal invasion arise close together from a single crypt or from dysplastic surface epithelium as detached cell groups, the maximum horizontal extent must
encompass all the foci of invasion in the immediate area and the horizontal extent should be measured from the edge at which invasion is first seen to the most distant edge at which invasion is detected.  

3. where several foci of invasion arise in one single piece of cervical tissue as separate foci of invasion, but in close proximity (see section below on MEASUREMENT OF MULTIFOCAL CARCINOMAS), either as contiguous tongues of invasion or detached epithelial groups, the maximum horizontal extent is taken from the edge at which invasion is first seen to the most distant edge at which invasion is detected. The small amount of intervening tissue with no invasion (usually with in situ neoplasia) is included in the measurement.

Measurement of depth of invasion (Figure 2)

The maximum depth of invasion must be measured in all cases. This measurement is taken from the base of the epithelium (surface or crypt) from which the carcinoma arises to the deepest point of invasion, as specified in the FIGO classification. If the deepest point of invasion involves the deep margin of the specimen, comment should be made regarding the possibility of underestimation of the depth of invasion; this is particularly applicable to loop/cone specimens. When the invasive focus is in continuity with the dysplastic epithelium from which it originates, this measurement is straightforward. If the invasive focus or foci are not in continuity with the dysplastic epithelium, the depth of invasion should be measured from the tumour base (deepest focus of tumour invasion) to the base of the nearest dysplastic crypt or surface epithelium (Figure 2, measurements ‘a’ and ‘c’). If there is no obvious epithelial origin despite multiple levels of the tissue block, the depth is measured from the tumour base (deepest focus of tumour invasion) to the base of the nearest surface epithelium, regardless of whether it is dysplastic or not (Figure 2, measurement ‘d’).

There are some situations where it is impossible to measure the depth of invasion. In such cases, the tumour thickness may be measured and this should be clearly stated on the pathology report along with the reasons for providing the thickness rather than the depth of invasion. In such cases, the pathologist and clinician should equate the tumour thickness with depth of invasion for staging and management purposes.

Situations where it may be necessary to measure the tumour thickness rather than the depth of invasion include:

1. in some glandular lesions, it may be impossible to accurately assess where adenocarcinoma in situ (AIS) ends and where invasive adenocarcinoma begins. This is because, in general, identification of invasion in a glandular lesion is more difficult than in a squamous lesion and this is an area where a specialist opinion may be of value. In some cases where the thickness is measured (from the epithelial surface to the deepest point of the tumour) because the point of origin is impossible to establish, this may result in overestimation of the depth of invasion.
2. in ulcerated tumours with no obvious origin from overlying epithelium, the thickness may need to be measured. In this situation, measurement of tumour thickness may result in an underestimate of the depth of invasion.
3. uncommonly, squamous carcinomas, adenocarcinomas and other morphological subtypes are polypoid with an exclusive or predominant exophytic growth pattern. In such cases, the carcinoma may project above the surface with little or even no invasion of the underlying stroma. These should not be regarded as in-situ lesions and the tumour thickness will need to be measured in such cases (from the surface of the tumour to the deepest point of invasion). Depth of invasion i.e. the extent of infiltration below the level of the epithelial origin, should not be provided in these cases as it may not be a true reflection of the biological potential of such tumours.

Avoid the term microinvasive carcinoma

The term “microinvasive carcinoma” appears in the 2018 FIGO staging system for cervical cancer where it is equated with stage IA disease. However, use of the term “microinvasive carcinoma” has different
connotations in different geographical areas. For example, in the United Kingdom, microinvasive carcinoma was considered to be synonymous with FIGO stage IA1 and IA2 disease in most, but not all, institutions (some used the term “microinvasive carcinoma” to denote only FIGO stage IA1 tumours). In the United States and Canada where the Lower Anogenital Squamous Terminology (LAST) recommendations have been adopted, the term superficially invasive squamous cell carcinoma (SISCCA) is used to describe FIGO stage IA1 tumours with negative margins, and the term “microinvasive squamous cell carcinoma” is no longer in routine use. Thus, in order to avoid confusion, it is recommended to avoid using the term “microinvasive carcinoma” for all morphological subtypes and to use the specific FIGO stage.

Measurement of multifocal carcinomas

Early invasive carcinomas of the cervix, especially squamous, are sometimes multifocal comprising tumours that show multiple foci of invasion arising from separate sites in the cervix and separated by uninvolved cervical tissue. Specifically, multifocal tumours should be diagnosed if foci of invasion are:

- separated by blocks of uninvolved cervical tissue (levels must be cut to confirm this)
- located on separate cervical lips with discontinuous tumour, not involving the curvature of the canal
- situated far apart from each other in the same section (see below).

The individual foci of stromal invasion may be attached to, or discontinuous from, the epithelium from which they arise. Multifocal carcinomas should not be confused with the scenario in which tongues or buds of invasion originate from more than one place in a single zone of transformed epithelium and will, over time, coalesce to form a single invasive tumour which represents unifocal disease (and should be measured as indicated above, in three dimensions).

The frequency of multifocality in FIGO stage IA1 cervical squamous carcinomas has been reported to be between 12 and 25% although multifocality in larger, advanced tumours is uncommon. There are few (and some rather dated) guidelines regarding measurement of multifocal carcinomas. Although pre-invasive disease may be present, when foci of stromal invasion arise from separate sites or are separated by cervical tissue without invasion (after levels/deeper sections have been cut to confirm this), the foci of invasion should be measured separately, in 3 dimensions, as described above, and staged according to the dimensions of the larger/largest tumour with a clear statement that the tumour is multifocal. However, in the last of the scenarios mentioned above (foci of stromal invasion situated far apart from each other in the same section) measurement of the multifocal disease is problematical. Options include measuring from the edge of one invasive focus to the edge of the furthest invasive focus according to FIGO guidelines (irrespective of the distance between foci of invasion), adding the maximum horizontal extent of each invasive focus together (which clearly does not reflect the biological potential of the individual invasive foci) or regarding widely separated foci as representing small independent areas of invasion. Two recent studies have regarded such lesions as representing multiple foci of invasion (multifocal FIGO IA1 carcinomas) if the foci of invasion are clearly separated. An arbitrary minimum distance of 2 mm between each separate focus of invasion has been applied in the 2 studies. Follow-up of patients in these two studies, which include a combined total of 46 cases of “multifocal IA1 cervical squamous carcinomas” treated by local excisional methods (loop/cone excision) with margins clear of premalignant and malignant disease, has shown no evidence of recurrent premalignant or malignant disease with median follow-up periods of 45 months and 7 years respectively. Moreover, one of the studies also showed that the prevalence of residual pre-invasive (20%) and invasive disease (5%) on repeat excision were comparable to data available for unifocal FIGO stage IA1 cases. These studies included cases which would have been regarded as FIGO stage IB1 in the 2009 staging system (but IA in the 2018 staging system) had the horizontal extent been measured from the edge of one invasive focus to the edge of the furthest invasive focus, as per FIGO guidelines. Although limited by a relatively small number of cases and the selection of an arbitrary distance of separation of 2 mm, the findings support the hypothesis that with regard to tumour staging and management, it may be appropriate to consider superficial, widely separated foci of invasion as representing multifocal lesions, to measure each focus separately, and to determine the FIGO stage on the basis of the invasive focus with the higher/highest FIGO stage. Although the International Collaboration on Cancer Reporting (ICCR) does not have a mandate to implement an approach...
based only on 2 studies involving 46 patients in total, the ICR recommends that this approach be considered and discussed at the Tumour Board/MDT meetings to avoid unnecessary surgery in young patients who wish to preserve their fertility in this specific clinical situation. This approach needs to be verified by additional larger collaborative studies and trials. It is also stressed that in such cases, the tissue blocks containing the invasive foci and those in between should be levelled to confirm that the invasive foci are truly separate and ensure that there is no occult stromal invasion in the intervening areas. If this approach is adopted, the pathology report should clearly indicate how the measurements have been obtained to arrive at a diagnosis of multifocal invasion, provide the dimensions of the separate foci of invasion and indicate how the FIGO stage has been ascertained. Such cases may need to be referred to cancer centres for review and, as indicated above, should be discussed individually at the Tumour Board/MDT meeting. There have been no similar studies for multifocal adenocarcinomas but anecdotally these are less common than multifocal squamous carcinomas and until further evidence becomes available, a similar approach is recommended.

**Measurement of tumour volume**

In most studies, tumour size is based on measurement of two dimensions but in a few studies, tumour volume (based on the three measured tumour dimensions) has been shown to predict prognosis more reliably than measurements in only one or two dimensions. Some older studies have suggested tumour volume as a reliable prognostic factor for early stage tumours: a volume of less than $420 \, \text{mm}^3$ has been suggested to be associated with no lymph node metastasis.\(^{24,26}\) This is one of the main reasons for recommending that three tumour dimensions (two of horizontal extent and one of depth of invasion or tumour thickness) are provided. However, only a few centres continue to routinely factor tumour volume into patient management.

**Figure 1: Measurement of cervical tumours in three dimensions**

CIN3 with involvement of endocervical gland crypts is represented by the dark blue-coloured areas, non-dysplastic squamous epithelium is pink, and grey areas indicate foci of stromal invasion. The depth of invasion, (a), and horizontal tumour dimension/width, (b) are measured in unifocal disease. **Third dimension:** This dimension is determined by calculating the block thickness (usually 2.5 - 3.0 mm) from the macroscopic specimen dimensions and multiplying this by the number of sequential blocks through which the invasion extends.
Figure 2: Measurement of width and depth of invasion in cervical tumours

The dark blue-coloured areas represent CIN3 with involvement of endocervical gland crypts, non-dysplastic squamous epithelium is pink, and grey areas indicate foci of stromal invasion.

**Depth of invasion**: when invasion originates from the surface epithelium, (a), or gland crypts (b and c), the depth of invasion is taken from the base of the epithelium from which the invasive carcinoma arises, to the deepest focus of invasion, as specified in the FIGO classification. Measurements are taken in the same way, regardless of whether the invasive foci remain attached to the gland crypt (b) or not (c). Where invasion occurs and no obvious surface (or crypt) epithelial origin is seen, the depth of invasion is measured from the deepest focus of tumour invasion, to the base of the nearest non-neoplastic surface epithelium, (d).

**Horizontal dimension/width in unifocal tumours**, (e): this is measured in the slice of tissue in which the width is greatest (from the edge at which invasion is first seen, to the most distant edge at which invasion is identified), in sections where the foci of invasion arise in close proximity to each other, even if those foci are separated by short stretches of normal epithelium.

↑ Back

**Note 8 – Histological tumour type (Core)**

All cervical carcinomas should be typed according to the 2014 World Health Organization (WHO) classification. Carcinosarcoma is also included since, although it is included in the category of mixed epithelial and mesenchymal tumours, it is essentially a carcinoma which has undergone sarcomatous differentiation/metaplasia. The major subtypes of cervical carcinoma are squamous cell carcinoma (SCC), adenocarcinoma (with various subtypes), adenosquamous carcinoma and neuroendocrine tumours. While it is beyond the remit of this document to detail the morphological appearances of the different tumour types in detail, a few points should be noted.

SCCs are nearly all caused by high-risk human papillomavirus (HPV) with rare exception and are subclassified by the WHO based on their histological growth pattern and the presence of keratinization. However, the subclassification of SCC seems to have little or no bearing on clinical behaviour and so it is not considered necessary to specify the subtype (keratinizing, papillary, basaloid, warty, verrucous etc). However, it may be useful to record unusual subtypes, for example lymphoepithelioma-like, since the behaviour of these is not well established.

There are several subtypes of cervical adenocarcinoma, the most common being the usual type which, in the majority of cases, is associated with high-risk HPV. The other, less common subtypes (gastric type, mesonephric, clear cell and others) are generally unassociated with HPV infection and have different and distinct histologic appearances. While there is limited information regarding the clinical behaviour of the adenocarcinoma subtypes, it is now well established that gastric type adenocarcinomas of the cervix (adenoma malignum or mucinous variant of minimal deviation adenocarcinoma is the morphologically well
differentiated end of the spectrum of gastric type adenocarcinoma) have a particularly aggressive behaviour with poor prognosis, even in early stage disease.\textsuperscript{10-32} Therefore, it is extremely important from both a prognostic stance as well as an aetiologic and epidemiologic perspective (in light of widespread HPV vaccination programs) to correctly identify these tumour subtypes. The ubiquitous use of and reliance on p16 immunohistochemistry to diagnose cervical adenocarcinoma may cause diagnostic problems for HPV negative tumours, since these do not exhibit the diffuse block-type immunoreactivity characteristic of HPV-related tumours (see \textbf{NOTE 15 - ANCILLARY STUDIES}).\textsuperscript{33,34} In addition, in the era of molecular characterization and targeted therapy, correct identification of the tumour subtypes will be even more crucial for understanding tumour biology and discovery of potential therapeutic targets.

Adenosquamous carcinomas (defined in WHO 2014 blue book as a malignant epithelial tumour comprising both adenocarcinoma and squamous carcinoma\textsuperscript{27}) are usually related to high-risk HPV. To make a diagnosis of adenosquamous carcinoma, malignant squamous and glandular components should be identifiable on routine haematoxylin and eosin stained sections. The demonstration of foci of intracytoplasmic mucin by mucin stains in an otherwise typical squamous carcinoma should not result in diagnosis of an adenosquamous carcinoma. Carcinomas which lack evidence of squamous differentiation (intercellular bridges, keratinisation) but have abundant mucin-producing cells should be diagnosed as poorly-differentiated adenosquamous. Adenosquamous carcinoma should also be distinguished from a spatially separate squamous carcinoma and adenocarcinoma, which occasionally occurs. While some studies have indicated a worse outcome than pure squamous or adenocarcinomas, there is not robust evidence to confirm these findings.\textsuperscript{35,36}

Primary serous carcinoma of the cervix is exceedingly rare and some doubt its existence, although it is included in the 2014 WHO Classification. Most cases reported as primary cervical serous carcinoma are likely to represent a metastasis from the corpus or extraterine sites or a usual HPV-related adenocarcinoma with marked nuclear atypia. Metastasis should be excluded before diagnosing a primary cervical serous carcinoma. Usual type cervical adenocarcinomas can have a papillary growth pattern and may show high-grade nuclear atypia, which can mimic serous carcinoma. Whether true p53 mutation-associated serous carcinoma of the cervix exists is unresolved at this time.

While endometrioid type adenocarcinoma of the cervix is a subtype listed in the 2014 WHO classification, in the past this has been an over-used diagnostic category and some even doubt its existence as a primary cervical neoplasm. Most adenocarcinomas classified as primary cervical endometrioid adenocarcinomas in the literature represent usual type cervical adenocarcinomas with mucin depletion. These are different from true endometrioid type adenocarcinomas of the uterine corpus or adnexa which are driven by hormones and not HPV-associated. If endometrioid adenocarcinoma occurs as a primary neoplasm in the cervix, it is most likely in the setting of endometriosis and has the same histologic and immunohistochemical profiles as endometrioid adenocarcinomas of the uterine corpus or ovary. As with serous carcinoma, extreme caution should be exercised before diagnosing a primary cervical endometrioid adenocarcinoma.

Neuroendocrine carcinomas (NECs) (small cell and large cell neuroendocrine carcinoma) are uncommon but well described in the cervix and can occur in pure form or associated with another tumour type, typically adenocarcinoma, squamous carcinoma or adenosquamous carcinoma. These are referred to in the WHO 2014 blue book as high-grade neuroendocrine carcinomas. The term ‘small cell neuroendocrine carcinoma’ is preferred to ‘small cell carcinoma’ since a small cell variant of squamous carcinoma occurs and if the term “neuroendocrine” is not applied, this may result in confusion. When mixed with another tumour type, the percentage of the neuroendocrine component should be given. Regardless of the percentage of NEC, it is recommended that the tumour be reported as mixed since all tumours containing a component of NEC have a very poor prognosis and the NEC component may be underestimated in a limited sample.\textsuperscript{37} Several studies of small cell neuroendocrine carcinomas of the cervix have shown that adjuvant chemotherapy after surgery for early stage disease provides significant clinical benefit compared to surgery alone and therefore, it is extremely important to correctly diagnose any component of NEC. Additionally, in many institutions surgical resection is not undertaken for a NEC even if early stage but instead chemotherapy treatment is given. Diagnosing NEC or a component of NEC can be difficult, especially in small samples, but a combination of synaptophysin, chromogranin, CD56, TTF1 and p63 has been shown to be helpful in making the distinction between NEC and poorly-differentiated non-NEC (see \textbf{NOTE 15 - ANCILLARY STUDIES}).\textsuperscript{38,39}
WHO classification of tumours of the uterine cervix

Epithelial tumours

Squamous tumours and precursors

Squamous intraepithelial lesions

- High-grade squamous intraepithelial lesion 8077/2
- Squamous cell carcinoma, not otherwise specified 8070/3
- Keratinizing 8071/3
- Non-keratinizing 8072/3
- Papillary 8052/3
- Basaloid 8083/3
- Warty 8051/3
- Verrucous 8051/3
- Squamotransitional 8120/3
- Lymphoepithelioma-like 8082/3

Glandular tumours and precursors

- Adenocarcinoma in situ 8140/2
- Adenocarcinoma 8140/3
- Endocervical adenocarcinoma, usual type 8140/3
- Mucinous carcinoma, NOS 8480/3
  - Gastric type 8482/3
  - Intestinal type 8144/3
  - Signet-ring cell type 8490/3
- Villoglandular carcinoma 8263/3
- Endometrioid carcinoma 8380/3
- Clear cell carcinoma 8310/3
- Serous carcinoma 8441/3
- Mesonephric carcinoma 9110/3
- Adenocarcinoma admixed with neuroendocrine carcinoma 8574/3

Other epithelial tumours

- Adenosquamous carcinoma 8560/3
- Glassy cell carcinoma 8015/3
- Adenoid basal carcinoma 8098/3
- Adenoid cystic carcinoma 8200/3
- Undifferentiated carcinoma 8020/3

Neuroendocrine tumours

- Low-grade neuroendocrine tumour
  - Carcinoid tumour 8240/3
  - Atypical carcinoid tumour 8249/3

- High-grade neuroendocrine carcinoma
  - Small cell neuroendocrine carcinoma 8041/3
  - Large cell neuroendocrine carcinoma 8013/3

Mixed epithelial and mesenchymal tumours

- Carcinosarcoma 8980/3

The morphology codes are from the International Classification of Diseases for Oncology (ICD-O). Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour; /2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours.

Note 9 – Histological tumour grade (Non-core)

Grading of cervical carcinoma

Tumour grade is regularly included in histopathology reports of cervical SCC and adenocarcinoma (ACA). However, at present no particular grading system(s) has achieved universal acceptance and grading of these tumours remains of uncertain clinical value.\(^{40-42}\) For example, grade is not amongst the factors considered in determining the Gynecology Oncology Group (GOG) score which is used to assess the need for adjuvant therapy following surgery for low-stage cervical carcinomas.\(^{43}\) Not uncommonly, studies that assess grade as a potential prognostic variable provide no details of the grading system employed, and this is also true of large multicentre investigations such as SEER analyses.\(^{44,45}\) For these and other reasons (discussed below), tumour grading is not listed as a required but rather a recommended element. Furthermore, no particular grading system for squamous carcinoma or adenocarcinoma is recommended.

General considerations

1. As with tumours arising in other anatomical sites, grading of cervical carcinomas has a considerable subjective component and this probably explains, at least in part, the variable proportion of well, moderately, and poorly-differentiated tumours reported in different studies. However, some investigators have demonstrated reasonable intra- and inter-observer agreement using more complex multifactor grading schemes in SCC (discussed below).

2. Almost all cervical SCCs are HPV-associated and given that HPV-associated SCCs very commonly have a “basaloid” morphology with minimal keratinisation, they are very commonly poorly-differentiated.

3. Most clinically advanced cervical carcinomas are treated with primary chemoradiation rather than surgery and histological sampling may be limited to a small diagnostic biopsy. This may not be fully representative due to tumour heterogeneity and could be potentially misleading as regards tumour differentiation or grade.\(^{40}\) This may be particularly relevant since less differentiated appearing tumour elements may be located more deeply towards the invasive margin.\(^{41}\)

4. There is an implicit correlation between tumour subtype and grade in certain cervical carcinomas and therefore a separate grade may not be applicable. For example, pure villoglandular ACA of the cervix is by definition a low-grade neoplasm while serous and clear cell carcinoma, as in the endometrium, are considered high-grade by default. Similarly, ‘gastric-type’ cervical ACAs and NECs are clinically aggressive regardless of their histological pattern and therefore are best considered high-grade automatically.\(^{30,31}\) There is no published grading system for cervical mesonephric ACAs.

Several variants of cervical SCC are also recognised, although most do not differ from conventional SCC in terms of prognosis or therapy.\(^{46}\)

5. It is uncertain whether a truly ‘undifferentiated’ cervical carcinoma should be regarded as a separate tumour subtype analogous, for example, to similar tumours arising in the endometrium.

6. Grading of very small superficially (‘early’) invasive carcinomas of either squamous or glandular type is probably not possible or relevant.

Grading of Cervical SCC

Historically, cervical SCCs were graded using Broder’s system or modifications thereof based upon the degree of keratinisation, cytological atypia and mitotic activity. In some schemes, the pattern of invasion (pushing versus infiltrating) has also been taken into account. Traditionally, SCCs have also been subclassified into large cell keratinising, large cell non-keratinising and small cell non-keratinising categories, with these sometimes being regarded as approximately equivalent to well, moderately and poorly-differentiated, respectively. As noted above, this raises the issue whether such categorisation represents a tumour subtype (arguably not further graded), or a grade within a spectrum of a single type of tumour. It should be noted that some studies have found that the keratinising variant of large cell SCC actually has a poorer prognosis.
than the non-keratinising variant, an apparently paradoxical finding if keratinisation is deemed to be evidence of better differentiation. It is also uncertain what proportion of “small cell SCCs” reported in the older literature would now be classified as high-grade NECs (small cell NEC), and this could potentially bias the supposedly poor outcome of this tumour category.

More complex multifactor grading systems (MGS) that include both tumour and host/stromal parameters have been assessed in cervical carcinomas, mainly SCC.\textsuperscript{47-51} For example, the system employed by Stendahl et al,\textsuperscript{47} based upon that used in head and neck SCC, comprised eight features, 4 of which were tumour-related (growth pattern, differentiation, pleomorphism and mitoses) and four of which were stromal-related (pattern of invasion, stage/depth of invasion, vascular invasion and inflammatory reaction). Each factor was scored from 1 to 3 and thus the potential total MGS score ranged from 8-24 points. Simplified modifications to the MGS have also been described including systems that selectively focus upon the invasive tumour border or the patterns of tumour invasion.\textsuperscript{52-55} However, the “cut-off value” for tumour grade has varied in different studies and not all have demonstrated a correlation with prognosis.\textsuperscript{41,56,57} At present, none of these grading systems has been widely adopted in routine diagnostic practice.

**Grading of Cervical ACA**

As with SCC, it is controversial whether grading has independent prognostic value in cervical ACA. Whilst a correlation between higher grade and adverse outcomes has been reported,\textsuperscript{58-62} at least for poorly differentiated tumours, this has not been a universal finding.\textsuperscript{63,64} It should also be noted that some studies have included a variable proportion of less common histological subtypes such as adenosquamous carcinoma, mesonephric, gastric-type and clear cell carcinoma\textsuperscript{58,61,62} and often tumour details are not provided. Therefore, it is not clear whether the reported grading data are applicable to usual-type cervical ACA or have been biased by the inclusion of other more aggressive tumour subtypes (for example, gastric-type ACA).

Most grading systems for cervical ACA have been based upon the relative proportion of glandular differentiation, typically following the FIGO system for endometrial endometrioid adenocarcinoma (EEC). However, the maximum permitted extent of solid growth for a grade 1 cervical ACA has been variably specified to be 5%\textsuperscript{65,66} or 10%.\textsuperscript{62,67} As with EEC, an upward grade adjustment has been suggested for those tumours exhibiting more marked cytological atypia. However, it is pertinent that usual-type cervical ACAs typically demonstrate more marked nuclear atypia, mitotic and apoptotic activity than architecturally similar EECs.\textsuperscript{68} There are no separate grading systems for the various non-HPV related cervical ACAs.

Recently, a system of assessing cervical ACAs based upon their invasive growth pattern has been developed, and this has been shown to be reproducible amongst pathologists and to correlate with the risk of lymph node metastasis and patient outcomes.\textsuperscript{69-72} If these findings are confirmed by additional studies it may be argued whether this system could be considered a complement to, or even an alternative to, conventional grading. The latter has traditionally been based upon the cytoarchitectural pattern of the neoplasm itself but as noted above, tumour-stromal relationships including the pattern of stromal invasion have been included in earlier grading schemes of cervical SCC.

**Grading of Cervical Adenosquamous Carcinoma**

Although it has been suggested that adenosquamous carcinomas are graded on the basis of the degree of differentiation of both the glandular and squamous components, there is no well-established grading system for these neoplasms which has been shown to be of prognostic significance.
Note 10 – Lymphovascular invasion (Core)

Lymphovascular invasion (LVI) does not affect FIGO or TNM staging (for example if there is LVI in tissues outside the cervix but the tumour itself is confined to the cervix, this is still FIGO stage I) but should be clearly documented in the pathology report. The significance of LVI in cervical carcinoma has been debated for predicting overall survival (OS), disease free interval (DFI), recurrence free survival (RFS) and regional lymph node metastasis for decades. Although studies conflict, there is general agreement that LVI is an independent predictor of adverse outcome.41,73-82 Early studies indicated that LVI was an independent predictor of DFI with one study reporting a 1.7 times higher rate of recurrence in patients with LVI compared to those without LVI in low-stage cervical carcinoma.75 This has been confirmed in later studies, particularly in low-stage (FIGO stage IB) cervical carcinoma.41 The significance of LVI in superficially invasive squamous cell carcinoma (SISCCA) is unclear, likely due to the rarity of adverse outcomes including lymph node metastasis in SISCCA. Studies have shown that LVI does not predict lymph node metastasis in cases of SISCCA with a depth of invasion of \(<3\) mm.83-86

Lack of standardised criteria and marked variability in recognition of LVI have undoubtedly lead to conflicting outcomes in previous studies. Fixation retraction around tumour cell groups is a well-recognized artifact which mimics LVI. Features that may help in the recognition of LVI include a tumour nest within a space associated with other vascular structures, the presence of an endothelial lining, adherence of the tumour cell group to the side of the space, the contour of the intravascular component matching the contour of the vessel and the presence of adherent fibrin. Immunohistochemical demonstration of an endothelial cell lining may assist but is not performed routinely. D2-40 (recognizing lymphatic endothelium) and CD31 and CD34 (recognizing both lymphatic and blood vascular endothelium) may be useful in confirming the presence of LVI.87-90

In rare situations when specimens are severely traumatised or diathermied, LVI may be suspected but it may not be possible to reliably determine whether or not LVI is present. In these circumstances ‘indeterminate’ should be recorded in the reporting guide, although it is expected this will be a rare response.

Most studies which have examined the significance of LVI in cervical carcinoma have not distinguished between lymphatic and blood vessel invasion and there is little evidence to support separating out the type of invasion, especially since this is not reliable in haematoxylin and eosin stained sections. Occasional studies have found blood vessel invasion to have a worse prognosis than lymphatic invasion and to be a predictor of ovarian involvement.91 However, there is insufficient evidence to warrant inclusion of blood vessel and lymphatic invasion as separate data items.

↑ Back

Note 11 – Coexistent pathology (Core and Non-core)

Carcinomas of the cervix are often associated with premalignant precursor lesions, which are mostly squamous or glandular in type. Their pathology is well described and illustrated in the WHO 2014 Classification of Tumours of Female Reproductive Organs and a number of published reviews.27,92,93 There are also numerous benign squamous or glandular lesions which can be broadly classified as inflammatory, metaplastic and neoplastic. Their importance is in recognizing the lesions as benign as they can morphologically mimic premalignant or malignant glandular or squamous lesions, and result in a false positive diagnosis.

It is important to report co-existing premalignant lesions and document whether they involve resections margins since this may influence patient management and follow up. All clearly defined premalignant lesions are caused by HPV. The terminology of HPV-associated premalignant squamous lesions was revised in WHO 2014 to Squamous Intraepithelial Lesion (SIL).94 The change also harmonizes with The Bethesda System for the reporting of cytological abnormalities in cervical smears. Squamous intraepithelial lesions are divided into low-grade SIL (LSIL) which is a viral infection with a high spontaneous resolution rate, and high-grade SIL
HSIL which is a true premalignant lesion that can progress to SCC. The corresponding cervical intraepithelial neoplasia (CIN) terms can be included in parentheses.

Adenocarcinoma in situ (AIS) is the HPV-associated precursor lesion of usual HPV-related cervical adenocarcinoma. High-grade cervical glandular intraepithelial neoplasia (HG CGIN) is an alternative terminology used in some jurisdictions.95 Stratified mucin producing intraepithelial lesion (SMILE) is a premalignant lesion with morphological overlap between SIH and AIS. In WHO 2014, it is regarded as a variant of AIS (and should be coded as such) but others consider it a form of high-grade reserve cell dysplasia and report it separately.96,97

The precursor lesions of non-HPV-related cervical adenocarcinomas are not well defined but lobular endocervical glandular hyperplasia (LEGH), atypical lobular endocervical glandular hyperplasia (ALEGH) and adenocarcinoma in situ of gastric type have been proposed as likely precursor lesions of gastric type adenocarcinoma of the cervix.98

Note 12 – Extent of invasion (Core)

The involvement of any extracervical structures by invasive tumour should be documented. Documentation of the involvement of various extracervical tissues is prognostically significant and is important for tumour staging. Involvement of the pelvic side-wall, vagina, ovary, fallopian tube, parametria, rectum and bladder upstage the tumour. Involvement of the uterine body, whilst not formally part of FIGO or TNM staging, has also been shown to be of prognostic significance.99 Documentation of the extent of invasion is also important for correlation with clinical and radiological findings.

The parametria are composed of fibrous tissue, which surrounds the supravaginal part of the cervix and separates this part of the cervix anteriorly from the bladder and posteriorly from the rectum. The fibrous parametrial tissue extends onto the sides of the supravaginal cervix and between the layers of the broad ligaments. The fibrous connective tissue around the isthmus at the cervix/lower uterine segment junction should be regarded as part of the parametria and included in the sampling of parametrial tissue. Lymph nodes and the uterine blood vessels and lymphatics that supply and drain the cervix are contained within the fibrous parametrial tissue.

The uterine body includes both endometrial (glandular/stromal) and myometrial structures.

If the bladder or rectum is involved, the pathologist should state which compartments are infiltrated; in particular, if the bladder or rectal mucosa is involved, this implies that the tumour is stage IVA at least.

Lymphovascular invasion (LVI) should be documented wherever it is identified, but anatomical structures where there is only LVI and no direct stromal infiltration, should not be recorded as being involved by tumour and the presence of LVI should not alter the FIGO stage.

Note 13 – Margin status (Core and Non-core)

The status of all surgical resection margins should be recorded (ectocervical, endocervical, radial/deep stromal and vaginal cuff). At the time of specimen grossing, it may be useful to ink the various resection margins with different colours to assist precise margin recognition.

The recording of margin involvement by tumour is a core data element. When invasive carcinoma is close to a surgical margin, documentation of the distance to the margin is non-core. No data are available to indicate the optimal margin of clearance of carcinoma in simple hysterectomy, trachelectomy, cone or loop biopsy
specimens. Consistent recording of the distance to the margins will enable data to be collected prospectively and provide evidence for future practice. A small number of retrospective studies has assessed the impact of close margins on local and overall recurrence in patients undergoing radical hysterectomy for cervical cancer. The crude local recurrence rate was 20% in 284 patients with FIGO stage IB carcinomas with ‘close’ margins (close was defined as <1 cm) in one study. In the same study, patients with negative margins, defined as a clearance of ≥1 cm, had a crude recurrence rate of 11%. Another study of close surgical margins after radical hysterectomy in early-stage cervical cancer found that close surgical margins, defined as ≤5 mm, were associated with recurrence rates of 24% as compared with recurrence rates of only 9% in patients with negative margins. In the same study, close surgical margins were significantly associated with positive lymph nodes, parametrial involvement, larger tumour size, deeper stromal invasion and lymphovascular invasion.

In occasional cases where tumour involvement of the margin cannot be determined for various reasons (processing artifact, multiple pieces or poor tissue orientation), the margin status should be specified as “cannot be assessed” and the reason explained. In hysterectomy or trachelectomy specimens, the lateral radial margin may consist of parametrial soft tissue, which should be measured (see NOTE 3 -SPECIMEN DIMENSIONS), based on gross examination, and calculated into the margin evaluation. In contrast, anterior and posterior radial/deep stromal margins in a hysterectomy specimen will consist of cervical stromal tissue. The presence of margin involvement by HSIL, AIS or SMILE should be documented (core element); if not involved, the distance to the resection margin is a non-core element, although, as with invasive tumour, there are no data available to indicate the optimal margin of clearance. In hysterectomy specimens with stage IA or small IB carcinomas, the entire cervix should be assessed histologically to ensure an accurate measurement of the extent of the disease and surgical margins.

**Note 14 - Pathologically confirmed distant metastases (Core)**

Documentation of known metastatic disease is an important part of the pathology report and is important for tumour staging, patient management and prognostication. Such information, if available, should be recorded in as much detail as is possible including the site of involvement and reference to any relevant prior surgical pathology or cytopathology specimens.

**Note 15 - Ancillary studies (Non-core)**

**HPV testing**

Human papillomavirus (HPV) is universally accepted to play an aetiological role in cervical carcinogenesis and HPVs are detectable in over 95% of pre-invasive and invasive cervical carcinomas, with HPV 16 and 18 being the most frequent types. Molecular testing for HPV may occasionally be useful in a diagnostic scenario. For example, this may be useful in primary diagnosis when the differential includes an HPV-related cervical cancer and a non HPV-related neoplasm or in confirmation of a metastatic HPV-related cervical neoplasm.

**Immunohistochemistry**

It is beyond the scope of this document to provide a detailed review of the immunophenotype of cervical neoplasms but some relevant issues should be noted.
p16 Immunohistochemistry

Diffuse immunoreactivity (nuclear and cytoplasmic) for p16 is a surrogate marker for malignant or high-grade, premalignant epithelial lesions associated with high-risk HPV infections. In high-grade premalignant squamous lesions, this is referred to as “block type” immunoreactivity. AIS and high-risk HPV-associated cervical cancers also show strong diffuse p16 nuclear and cytoplasmic staining. However, it should be remembered that other gynaecological malignancies, for example uterine serous carcinoma and high-grade serous carcinoma of the ovary/fallopian tube typically exhibit such strong diffuse immunoreactivity with p16. This should be distinguished from focal/patchy (so-called “mosaic-type”) staining, which is not in keeping with a high-risk HPV associated neoplasm.

Immunohistochemistry: Cervical versus Endometrial Adenocarcinoma

Immunohistochemistry can be helpful in the differential diagnosis between a cervical and an endometrial adenocarcinoma. In the distinction between an endometrial and a cervical origin for an adenocarcinoma, the panels of markers which are useful will depend on the morphological subtype and not just the site of origin. In the distinction between a high-risk HPV-related (usual type) cervical adenocarcinoma and a low-grade endometrial endometrioid adenocarcinoma, the most useful immunohistochemical markers are p16 and hormone receptors (oestrogen receptor (ER) and progesterone receptor (PR)) with cervical adenocarcinomas exhibiting diffuse immunoreactivity with p16 and usually being negative or only focally positive with hormone receptors. In contrast, low-grade endometrial endometrioid adenocarcinomas are usually diffusely positive with hormone receptors and exhibit patchy “mosaic-type” staining with p16. Even when low-grade endometrioid adenocarcinomas exhibit diffuse positivity with p16, this is still usually patchy with alternating positive and negative areas. Vimentin (usually positive in low-grade endometrial endometrioid adenocarcinoma and negative in cervical adenocarcinomas) and CEA (usually positive in cervical adenocarcinomas and negative in low-grade endometrial endometrioid adenocarcinomas) may also be of value. However, it is stressed that there may be unexpected positive and negative staining reactions with any of the markers. HPV studies will be of value in such cases.

In the distinction between a high-risk HPV-related (usual type) cervical adenocarcinoma and a high-grade endometrial adenocarcinoma, p16 and hormone receptors are often of limited value. p53 immunohistochemistry and HPV studies may be of value in this scenario. Most uterine serous carcinomas and many other high-grade endometrial carcinomas exhibit mutation-type p53 staining (“all or nothing” staining) and are HPV negative. High-risk HPV-related cervical adenocarcinomas rarely, if ever, exhibit “mutation-type” p53 expression.

Immunohistochemistry of Non-HPV Related Cervical Adenocarcinomas

Non-HPV related cervical adenocarcinomas have a different immunophenotype than usual HPV related adenocarcinomas. They tend to be negative or only focally positive with p16 and some, such as gastric type adenocarcinomas, may exhibit mutation-type staining with p53. Gastric type adenocarcinomas are usually positive with gastric markers such as MUC6 and HIK1083 and are flat negative with hormone receptors. There is no specific immunohistochemical marker of mesonephric adenocarcinomas but they tend to be flat negative with hormone receptors and may stain with CD10 and GATA3. Clear cell carcinomas are usually hormone receptor negative, exhibit wild-type staining with p53 and may be positive with Napsin A and hepatocyte nuclear factor 1-beta.

Immunohistochemistry of Cervical Neuroendocrine Carcinomas

Cervical neuroendocrine carcinomas are variably positive with the neuroendocrine markers chromogranin, CD56, synaptophysin and PGP9.5. Of these, CD56 and synaptophysin are the most sensitive but CD56 lacks specificity. Chromogranin is the most specific neuroendocrine marker but lacks sensitivity with only about 50% of these neoplasms being positive. Chromogranin positivity is often very focal in small cell neuroendocrine carcinomas with punctate cytoplasmic immunoreactivity which is only visible on high-power magnification. A diagnosis of small cell neuroendocrine carcinoma can be made in the absence of neuroendocrine marker positivity if the morphological appearances are typical. Small cell neuroendocrine carcinoma may be only focally positive (often punctate cytoplasmic staining) or even negative with broad-
A diagnosis of large cell neuroendocrine carcinoma requires neuroendocrine marker positivity and most of these neoplasms are diffusely positive with broad-spectrum cytokeratins.

A high percentage of primary cervical neuroendocrine carcinomas are TTF1 positive, including some with diffuse immunoreactivity, and this marker is of no value in distinction from a pulmonary metastasis. Most cervical neuroendocrine carcinomas are diffusely positive with p16 secondary to the presence of high-risk HPV. Diffuse p63 nuclear positivity is useful in confirming a small cell variant of squamous carcinoma rather than small cell neuroendocrine carcinoma. However, occasional cervical neuroendocrine carcinomas exhibit p63 nuclear immunoreactivity.

**Note 16 – Lymph node status (Core)**

Lymph node status is one of the most important prognostic factors for survival in patients with cervical cancer. The 5-year survival rate decreases from 85 to 50% when lymph node metastases are identified. Radical hysterectomy or trachelectomy and pelvic lymphadenectomy are the standard of treatment in most centres for FIGO 2018 stage IB1, IB2 and IIA1 cervical carcinomas and, in some centres, for stage IA2 carcinomas. There is an increasing trend for a more conservative approach, such as loop/cone excision, in the treatment of FIGO stage IA2 and small stage IB1 carcinomas, particularly if additional risk factors such as lymphovascular invasion are absent. In such cases, lymphadenectomy is often performed. Lymphadenectomy may also occasionally be performed for bulky nodal metastases (>2 cm) which are resistant to radiotherapy and/or chemotherapy; debulking of enlarged pelvic nodes has been shown to reduce the risk of pelvic recurrence but does not benefit survival.

Core data items regarding lymph node status are restricted to the number of lymph nodes identified from the various sites and the number involved by tumour. However, some of the other parameters included below may be recorded if locally agreed and recording these parameters (size of lymph node metastasis, extracapsular spread, lymph node ratio) may be useful for future research.

Resected lymph nodes are categorised as regional (paracervical, parametrial, various pelvic lymph node groups, including obturator, internal, common or external iliac, presacral and lateral sacral, and para-aortic) or non-regional nodes (inguinal and other nodes). The FIGO 2018 staging system, unlike previous systems, includes lymph node status and is thus now closely aligned with the structure of the TNM Classification (see **Note 17 - Pathological Staging**). In the FIGO 2018 system, pelvic lymph node involvement is stage IIIC1 and para-aortic nodal involvement stage IIC2. In applying a TNM stage, regional lymph node metastases contribute to the N category, but non-regional node involvement is regarded as distant metastasis. One point to emphasise is that the TNM8 Classification takes into account the size of the nodal metastasis in assigning the N category. According to TNM8, macrometastases (MAC) are >2mm, micrometastases (MIC) are >0.2-2 mm and isolated tumour cells (ITCs) are up to 0.2 mm. MAC are regarded as pN1, MIC as pN1 (mi) and ITCs are pN0 (+). The 2018 FIGO staging states that MIC and ITCs can be recorded but this does not alter the tumour stage. The ICCR dataset authoring committee feel that this statement is ambiguous and can be interpreted in two ways. This could mean that a lower stage tumour is not upstaged to stage III in the presence of MIC or ITCs or alternatively that the tumour is already stage III and that it does not matter whether the metastatic disease is MIC or ITCs. Moreover, grouping MIC and ITCs together is in contradiction to the position in TNM8 where ITCs are regarded as node negative and MIC as node positive pN1(mi). It is hoped that this discrepancy will be clarified by FIGO.

According to the Union for International Cancer Control (UICC), a pelvic lymphadenectomy specimen will ordinarily include 6 or more lymph nodes, but if this node count is not met and the resected lymph nodes are negative, the carcinoma should still be classified as pN0. The mean or median number of lymph nodes removed during pelvic lymphadenectomy varies widely in different studies and ranges from 13 to 56 nodes. Apart from the arbitrary minimum number of nodes proposed by the UICC, there is no internationally accepted minimum for the number of resected lymph nodes required as part of a lymphadenectomy for
cervical cancer. A study by Inoue et al reported that the number of positive nodes was of greater prognostic significance than the presence of nodal metastasis per se\textsuperscript{118} and a more recent study showed that the number of lymph nodes with metastases is an independent risk factor for reduced survival in patients with cervical cancer.\textsuperscript{119}

In many centres, sentinel lymph node biopsy is now being undertaken in patients with presumed low-stage cervical carcinoma.\textsuperscript{104,120,121} Overall, in stage I cervical cancer the incidence of pelvic lymph node metastasis is approximately 10%\textsuperscript{122} and if the sentinel lymph node is negative, this avoids the morbidity associated with full pelvic lymphadenectomy in the remaining 90% of patients, i.e. sentinel lymph node biopsy is of value in reducing the requirement for a complete lymphadenectomy with its attendant morbidity in a patient population at low risk for lymph node metastases. With regard to the issue of “MIC” (which, as discussed, should be staged as pN1 (mi)) and the use of immunohistochemistry (usually cytokeratin AE1/AE3), a study by Juretzka et al found immunohistochemically-detected MIC in 8.1% of patients with initially reported “negative” nodes (comprising 4 of 976 or 0.41% of pelvic lymph nodes examined).\textsuperscript{123} The immunohistochemically-detected MIC were more frequent in tumours with lymphovascular invasion; another study showed that immunohistochemically-detected MIC were a risk factor for tumour recurrence.\textsuperscript{124} Other studies have shown higher rates of lymph node MIC in early stage cervical carcinomas for example, 10.1% of cases in a study by Cibula et al\textsuperscript{125} and 15% in a study by Lentz and co-workers.\textsuperscript{126} The latter study also showed that MIC were more likely in patients in whom larger numbers of lymph nodes were removed. A study by Horn et al revealed that lymph node MIC were prognostically significant; patients with MIC had a reduced 5-year survival rate compared with node-negative patients, but fared better than those patients with MAC.\textsuperscript{127} In the study by Cibula et al\textsuperscript{125} ITCs were detected in 4.5% of cases and were found to be of no prognostic significance. If sentinel lymph node biopsy is carried out, the number of nodes examined and the number of positive nodes should be recorded. It is acknowledged that there are few published data regarding MIC and ITCs in cervical cancer and until further data emerge it is recommended that these should be reported in the same way as ITCs at other sites.

The size of lymph nodes with metastatic carcinoma has been reported to be a prognostic factor in one study; patients with lymph nodes >15 mm in short-axis diameter had significantly lower survival rates than nodes of smaller size.\textsuperscript{128}

Lymph node ratio (LNR), the ratio of positive to negative lymph nodes, has been assessed in a wide range of different cancers. The significance of LNR in cervical carcinoma has only recently been evaluated and there is insufficient evidence to include this as a data item in the current dataset. However, in early stage cervical cancer, the LNR identifies node-positive patients with a worse prognosis\textsuperscript{129} and has been found to be an independent prognostic indicator of overall survival and disease-free survival in patients with SCC.\textsuperscript{130}

There are very few studies that assess the significance of extracapsular/extranodal spread of metastatic cervical carcinoma, and the item has not been included in this dataset. One study showed extracapsular spread to correlate with advanced stage disease, the number of involved nodes and the size of metastatic deposits.\textsuperscript{131} In another study, patients with extracapsular lymph node spread had a significantly lower 5-year recurrence-free survival rate compared to patients whose nodes showed no extracapsular spread.\textsuperscript{132}

The lymph node parameters considered in the last 3 paragraphs have not been included as specific data items due to a lack of supporting evidence. However, as indicated above, individual pathologists or institutions may choose to include some or all of these items in their own protocols. This may be useful for prospective data collection.
Note 17 – Provisional Pathological Staging Pre-MDTM (Core and Non-core)

FIGO staging is defined as a core item while TNM can also be used (non-core item- see below). A new FIGO staging system for cervical cancer was introduced in 2018. The main changes from the prior 2009 system are:-

1. The horizontal dimension of 7 mm is no longer considered in defining the upper boundary of a stage IA carcinoma.
2. Stage IB has been subdivided into IB1, IB2 and IB3 based on maximum tumour size.
3. Nodal status is included; the presence of nodal involvement upstages a tumour to stage IIIC, with IIIC1 indicating pelvic and IIIC2 indicating para-aortic nodal involvement. As discussed, the revised FIGO classification is now more closely aligned with the TNM classification.
4. Prior FIGO staging systems were based mainly on clinical examination but the 2018 staging system allows imaging and pathology findings to be taken into account to supplement clinical staging with respect to tumour size and extent in all stages. The notation of r (imaging) or p (pathology) should indicate the parameters that are used to allocate the case to stage IIIC; for example, if imaging indicates pelvic lymph node metastasis, the stage would be stage IIIC1r, and if confirmed by pathologic findings, it would be stage IIIC1p.

Table 1: 2009 and 2018 FIGO staging of carcinoma of the cervix uteri. Differences in the two staging systems are highlighted in red text.

<table>
<thead>
<tr>
<th>FIGO staging of carcinoma of the cervix uteri</th>
<th>2009</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stage I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded).</td>
<td></td>
<td>The carcinoma is strictly confined to the cervix uteri (extension to the corpus should be disregarded)</td>
</tr>
<tr>
<td>IA Invasive cancer identified only by microscopy, with deepest invasion ≤5mm and largest extension ≤7mm.</td>
<td>Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion &lt;5 mm²</td>
<td></td>
</tr>
<tr>
<td>IA1 Measured stromal invasion ≤3.0 mm in depth and extension ≤7 mm.</td>
<td>Measured stromal invasion &lt;3 mm in depth</td>
<td></td>
</tr>
<tr>
<td>IA2 Measured stromal invasion &gt;3 mm and ≤5 mm with an extension ≤7 mm.</td>
<td>Measured stromal invasion ≥3 mm and &lt;5 mm in depth</td>
<td></td>
</tr>
<tr>
<td>IB Clinically visible lesions limited to the cervix uteri or preclinical lesions greater than stage IA.</td>
<td>Invasive carcinoma with measured deepest invasion ≥5 mm (greater than stage IA), lesion limited to the cervix uteri⁸</td>
<td></td>
</tr>
<tr>
<td>IB1Clinically visible lesions ≤4 cm in greatest diameter</td>
<td>Invasive carcinoma ≥5 mm depth of stromal invasion and &lt;2 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>IB2 Clinically visible lesions &gt;4 cm in greatest diameter</td>
<td>Invasive carcinoma ≥2 cm and &lt;4 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>IB3</td>
<td>Invasive carcinoma ≥4 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td><strong>Stage II</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical carcinoma extends beyond the uterus, but not to the pelvic wall or to the lower third of the vagina</td>
<td>The carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall</td>
<td></td>
</tr>
<tr>
<td>IIA Without parametrial invasion</td>
<td>Involvement limited to the upper two-thirds of the vagina without parametrial involvement</td>
<td></td>
</tr>
<tr>
<td>IIA1 Clinically visible lesion ≤4.0 cm in greatest diameter</td>
<td>Invasive carcinoma &lt;4 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>IIA2 Clinically visible lesion &gt;4 cm in greatest dimension.</td>
<td>Invasive carcinoma ≥4 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>IIB With obvious parametrial invasion</td>
<td>With parametrial involvement but not up to the pelvic wall</td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney. On rectal examination, there is no cancer–free space between the tumour and the pelvic wall</td>
<td>The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or paraaortic lymph nodes&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>IIIA</td>
<td>No extension to the pelvic wall but involvement of the lower third of vagina</td>
<td>Carcinoma involves the lower third of the vagina, with no extension to the pelvic wall</td>
</tr>
<tr>
<td>IIIB</td>
<td>Extension on to pelvic wall and/or hydronephrosis or non-functioning kidney</td>
<td>Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to another cause)</td>
</tr>
<tr>
<td>IIIC</td>
<td>Involvement of pelvic and/or paraaortic lymph nodes, irrespective of tumour size and extent (with r and p notations)&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>IIIC1</td>
<td>Pelvic lymph node metastasis only</td>
<td></td>
</tr>
<tr>
<td>IIIC2</td>
<td>Paraaortic lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td>The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to stage IV</td>
<td>The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous edema, as such, does not permit a case to be allotted to stage IV</td>
</tr>
<tr>
<td>IVA</td>
<td>Spread of growth to adjacent organs</td>
<td>Spread of the growth to adjacent organs</td>
</tr>
<tr>
<td>IVB</td>
<td>Spread to distant organs</td>
<td>Spread to distant organs</td>
</tr>
</tbody>
</table>

**Notes**

- Imaging and pathology can be used, when available, to supplement clinical findings with respect to tumour size and extent, in all stages.
- The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.
- Adding notation of r (imaging) and p (pathology) to indicate the findings that are used to allocate the case to stage IIIC. For example, if imaging indicates pelvic lymph node metastasis, the stage allocation would be stage IIIC1r and, if confirmed by pathological findings, it would be Stage IIIC1p. The type of imaging modality or pathology technique used should always be documented. When in doubt, the lower staging should be assigned.

There are several difficulties inherent in the staging of carcinoma of the uterine cervix<sup>4</sup>: (i) there are difficulties in obtaining precise tumour measurements in low-stage disease (FIGO IA and IB); this has been discussed in **NOTE 7 - TUMOUR DIMENSION**. (ii) clinical staging, as previously recommended by FIGO may under or overestimate true anatomical extent of disease as it does not include information obtained from post-surgical pathology specimens or radiological/surgical techniques which may not be universally available. Reliance on clinical staging tends to occur in underdeveloped or under-resourced countries where surgical facilities and ancillary investigations (such as radiology and pathology) may be limited. As discussed, the 2018 FIGO staging systems allows incorporation of imaging and pathology findings. A provisional FIGO stage should be provided on the pathology report but the definitive stage is assigned at the tumour board/MDTM.

As stated, FIGO staging is defined as a core item while TNM is non-core. However, in many areas of the world, TNM staging UICC or American Joint Committee on Cancer (AJCC) versions) is used or even mandated in clinical and pathological practice. For example, in the United States, use of the AJCC system is required for

---

<sup>a</sup>FIGO staging systems allows incorporation of imaging and pathology findings. A provisional FIGO stage should be provided on the pathology report but the definitive stage is assigned at the tumour board/MDTM.
College of Surgeons Cancer Center accreditation, National Comprehensive Cancer Network (NCCN) Clinical decision guidelines implementation and for the College of American Pathologists (CAP) accreditation.
References


